Division of Endocrinology, Metabolism and Molecular Medicine, Northwestern University, Chicago, IL 60611, USA.
Menopause. 2011 Jun;18(6):603-10. doi: 10.1097/gme.0b013e3182014849.
Emerging evidence suggests that women with menopausal vasomotor symptoms (VMS) have increased cardiovascular disease (CVD) risk as measured by surrogate markers. We investigated the relationships between VMS and clinical CVD events and all-cause mortality in the Women's Health Initiative Observational Study (WHI-OS).
We compared the risk of incident CVD events and all-cause mortality between four groups of women (total N = 60,027): (1) no VMS at menopause onset and no VMS at WHI-OS enrollment (no VMS [referent group]), (2) VMS at menopause onset but not at WHI-OS enrollment (early VMS), (3) VMS at both menopause onset and WHI-OS enrollment (persistent VMS [early and late]), and (4) VMS at WHI-OS enrollment but not at menopause onset (late VMS).
For women with early VMS (n = 24,753), compared with no VMS (n = 18,799), hazard ratios (95% CIs) in fully adjusted models were as follows: major coronary heart disease (CHD), 0.94 (0.84-1.06); stroke, 0.83 (0.72-0.96); total CVD, 0.89 (0.81-0.97); and all-cause mortality, 0.92 (0.85-0.99). For women with persistent VMS (n = 15,084), there was no significant association with clinical events. For women with late VMS (n = 1,391), compared with no VMS, hazard ratios (95% CIs) were as follows: major CHD, 1.32 (1.01-1.71); stroke, 1.14 (0.82-1.59); total CVD, 1.23 (1.00-1.52); and all-cause mortality, 1.29 (1.08-1.54).
Early VMS were not associated with increased CVD risk. Rather, early VMS were associated with decreased risk of stroke, total CVD events, and all-cause mortality. Late VMS were associated with increased CHD risk and all-cause mortality. The predictive value of VMS for clinical CVD events may vary with the onset of VMS at different stages of menopause. Further research examining the mechanisms underlying these associations is needed. Future studies will also be necessary to investigate whether VMS that develop for the first time in the later postmenopausal years represent a pathophysiologic process distinct from the classic perimenopausal VMS.
新出现的证据表明,以替代标志物衡量,有更年期血管舒缩症状(VMS)的女性心血管疾病(CVD)风险增加。我们研究了妇女健康倡议观察研究(WHI-OS)中 VMS 与临床 CVD 事件和全因死亡率之间的关系。
我们比较了 4 组女性(共 60027 名)新发 CVD 事件和全因死亡率的风险:(1)绝经时无 VMS,WHI-OS 入组时无 VMS(无 VMS[参考组]),(2)绝经时 VMS,但 WHI-OS 入组时无 VMS(早期 VMS),(3)绝经时和 WHI-OS 入组时均有 VMS(持续 VMS[早期和晚期]),(4)WHI-OS 入组时 VMS,但绝经时无 VMS(晚期 VMS)。
对于早期 VMS(n=24753)的女性,与无 VMS(n=18799)的女性相比,完全调整模型中的风险比(95%CI)如下:主要冠心病(CHD),0.94(0.84-1.06);中风,0.83(0.72-0.96);总 CVD,0.89(0.81-0.97);全因死亡率,0.92(0.85-0.99)。对于持续 VMS(n=15084)的女性,与临床事件无显著关联。对于晚期 VMS(n=1391)的女性,与无 VMS 的女性相比,风险比(95%CI)如下:主要 CHD,1.32(1.01-1.71);中风,1.14(0.82-1.59);总 CVD,1.23(1.00-1.52);全因死亡率,1.29(1.08-1.54)。
早期 VMS 与 CVD 风险增加无关。相反,早期 VMS 与中风、总 CVD 事件和全因死亡率降低有关。晚期 VMS 与冠心病风险增加和全因死亡率增加有关。VMS 对临床 CVD 事件的预测价值可能因 VMS 在绝经不同阶段的发生而有所不同。需要进一步研究来研究这些关联背后的机制。未来的研究还需要调查在绝经后后期首次出现的 VMS 是否代表与经典围绝经期 VMS 不同的病理生理过程。